Deal-Making

Getinge pays $89m for Applikon to boost life sciences biz

Getinge has bought Applikon Biotechnology to expand its life sciences technologies business. Sweden’s Getinge announced it would pay SEK 840 million ($89 million) for Applikon last month. It said the Dutch bioreactor firm’s technology portfolio would bolster its biopharma segment. It cited Applikon’s range of systems for the research and production of vaccines and antibodies as well as those for the production of enzymes and bio-plastics as the main motivation. “Applikon Biotechnology has a strong portfolio of world class bioreactor solutions…

Twist to biopharma with Pandion antibody optimization expansion

Twist Bioscience will leverage its antibody optimization platform to help develop further autoimmune and inflammatory candidates for Pandion Therapeutics. The two firms have completed an initial project using Twist’s antibody optimization platform based on DNA sequencing technology and will now collaborate on further antibodies for autoimmune regulation. Twist Biopharma – a division of California-based Twist Bioscience – CEO Emily Leproust said the deal with Pandion “is an excellent example of how our antibody optimization solution can change the discovery and…

Lonza teams with 3D bioprinting firm Allevi

Lonza has partnered with 3D bioprinting materials firm Allevi citing growing biopharma demand for bespoke organs for drug discovery research. The collaboration – terms of which were not disclosed – will see the Swiss contract development and manufacturing organization (CDMO) combine its primary cells and culture media with Philidelphia-based Allevi’s range of bioprinter and bioink production technologies. The idea is to cater for biopharma developers looking to manufacture organs and tissues for drug discovery. Lonza said it collaborates with selected…

Biotech VC down 20% in US as policies drive away foreign investors, BIO

Reforms to a US national security regulation are putting off foreign investors and driving down VC investment in the biotech space by as much as 20 percent, says BIO’s David Thomas. In August 2018, Congress passed the Foreign Investment Risk Review Modernization Act (FIRRMA) as part of the Fiscal 2019 National Defense Authorization Act. The Act broadened the scope and oversight of the Committee on Foreign Investment in the United States (CFIUS) to include the review of foreign investments in companies…

The 12 trends of Christmas: A look back at 2019

CAR-T partnerships, Biopharma megamergers, biotech funding, and an eye on China. Bioprocess Insider presents the biggest stories of the year… through song! T’was the days before Christmas, And all through the dept. Not a story was breaking and journalists wept. So why not look back at the news of the year, The editor suggested over a beer… In the past twelve months Bioprocess Insider brought to you (To the tune of traditional Christmas song ‘The Twelve Days of Christmas’): A…

Novartis inks 5 years vector supply extension with Oxford Biomedica

Oxford Biomedica will keep supplying Novartis with the vectors needed to make Kymriah and other CAR-T products under a five-year deal extension. The new agreement will see Oxford Biomedica receive $75 million for manufacturing, undisclosed process development payments, a facility reservation fee as well as previously agreed royalties on chimeric antigen receptor (CAR-T) product sales. The extension deal also requires the firm ensure at least two manufacturing facilities are capable of commercial supply. Oxford Biomedica will make the vectors at…

Hemophilia A-OK! FTC thumbs up effectively closes Roche’s $4.3bn Spark buy

There is no risk of competitive harm between Roche’s approved hemophila A monoclonal antibody and Spark’s gene therapy candidates, say the US and UK competition bodies. In February, Swiss Biopharma firm struck a deal to buy Philadelphia, Pennsylvania-based Spark Therapeutics for $4.3 billion (€3.8 billion). Now after months of investigation by the US Federal Trade Commission (FTC), Roche is on the verge of closing the deal. The FTC’s concerns centered on the potential competitive harm of overlaps between Roche and…

Charles River bids $380m to buy cell therapy services firm HemaCare

HemaCare will boost Charles River Laboratories’ offering in the cell therapy materials and leukapheresis space – a market predicted to grow to $2 billion in the next decade. The deal will add expand Charles River’s cell therapy offering. HemaCare provides human primary cells as well as services used in the discovery, development and commercial production of cell therapies. Leukapheresis – the separation of white cells from blood samples – is a core HemaCare offering. The firm provides leukapheresis services for…

Sanofi wins US HHS $226m contract to expand PA vaccine capacity

The US Government has contracted Sanofi Pasteur to increase recombinant vaccine capacity at its Pennsylvania plant as part of US efforts to prepare for a flu pandemic. The US Department of Health and Human Services (HHS) shared details of the six-year, $226 million contract this week. Sanofi will work with the Biomedical Advanced Research and Development Authority to (BARDA) double capacity at the plant. The contract includes options that would see Sanofi retrofit a second facility to make adjuvant; develop…

AI will help Novartis make personalized meds, says Amazon

Amazon says Novartis’ personalized medicines operations will benefit from AI and machine learning collaboration. Novartis confirmed it had asked Amazon Web Services (AWS) to rejig is supply lines last week. The drug firm said it “will leverage AWS’s broadest portfolio of cloud services to build an enterprise-wide data and analytics platform that will transform business operations. According to AWS, the plan is to use artificial intelligence and machine learning to “reimagine” the Swiss firm’s manufacturing, supply chain, and delivery operations.…